350 rub
Journal №5 for 2012 г.
Article in number:
Studying of pharmacokinetic characteristics of a radiopharmaceutical on the basis of monopotassium salt of 1-hydroxyethylidenediphosphonic acid labeled with 188Re in rats with rhabdomyosarcoma M-1
Keywords: 1-hydroxyethylidenediphosphonic acid rhenium-188
Authors:
V.M. Petriev, V.K. Shiryaeva, O.A. Smorizanova , V.G. Skvortzov
Abstract:
The experimental data demonstrate that neoplastic process doesn-t modify considerably the pharmacokinetics of bone-seeking radiopharmaceutical 188Re-KHEDP in rats with rhabdomyosarcoma M-1. It is shown that 188Re-KHEDP doesn-t have selective affinity with tumor tissue. The processes of accumulation and elimination of radiopharmaceutical from soft tissues of rats with rhabdomyosarcoma are similar to the processes in control group of animals. The coefficients of differential level of accumulation of radioactivity in bones testify that there is no difference between absorption and retention of 188Re-KHEDP in bone tissue of normal rats and rats with tumor. Maximal bone-to-muscle and bone-to-blood ratios were 131,6±24,5 and 3,90±0,69 in the group of rats with rhabdomyosarcoma and 128,2±25,0 and 38,5±7,19 in the group of healthy rats respectively. The trace amounts of 188Re-KHEDP in thyroid gland show that the stability of this radiopharmaceutical is rather high both in rats with rhabdomyosarcoma M-1 and healthy ones.
Pages: 36-43
References
  1. Zhang H., Tian M., Li S., Liu J., Tanada S., Endo K. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients // Cancer Biother. Radiopharm. 2003. V. 18. № 5. P. 719-726.
  2. Liepe K., Runge R., Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain // J. Cancer Res. Clin. Oncol. 2005. V. 131. № 1. P. 60-66.
  3. Lambert B., de Klerk J.M. Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy // Nucl. Med. Commun. 2006. V. 27. № 3. P. 223-229.
  4. Lin W.Y., Hsieh J.F., Lin C.P., Hsieh B.T., Ting G., Wang S.J., Knapp F.F., Jr. Effect of reaction conditions on preparations of rhenium-188 hydroxyethylidene diphosphonate complexes // Nucl. Med. Biol. 1999. V. 26. P. 455-459.
  5. Lungu V., Niculae D., Bouziotis P., Pirmettis I., Podina C. Radiolabeled phosphonates for bone metastases therapy // J. Radioanal. Nucl. Chem. 2007. V. 273. № 3. P. 663-667.
  6. Lin W.Y., Lin C.P., Yeh S.J., Hsieh B.T., Tsai Z.T., Ting G., Yen T.C., Wang S.J., Knapp F.F., Jr, Stabin M.G. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases // Eur. J. Nucl. Med. 1997. V. 24. № 6. P. 590-595.
  7. Liepe K., Geidel H.H., Bergmann R., Haase M., Runge R., Kotzerke J.Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer // Nucl. Med. Commun. 2009. V. 30. № 9. P. 693-699.
  8. Casara D., Bonazza A. Rhabdomyosarcoma concentrating Tc-99m MDP // J. Nucl. Med. 1983. V. 24. № 11. P. 1082-1083.
  9. Wilkinson R.H., Jr, Gaede J.T. Concentration of Tc-99m methylenediphosphonate in hepatic metastases from squamous cell
    carcinoma // J. Nucl. Med. 1979. V. 20. № 4. P. 303-305.
  10. Senda M., Tamaki N., Torizuka K., Fujiwara Y., Kudo M., Tochio H., Ito H., Yamaguchi H., Saiki Y., Ikekubo K. Accumulation of Tc-99m methylene diphosphonate in calcified metastatic lesions of the liver from colonic carcinoma. Comparison with calcification on X-ray computed tomogram // Clin. Nucl. Med. 1985. V. 10. № 1. P. 9-12.
  11. Tsuji T., Yamamuro T., Kotoura Y., Matsumoto M., Tanaka H., Tanaka C., Toguchida J., Endo K., Sakahara H., Koizumi M. Uptake of 99Tcm-MDP in lung metastasis from osteosarcoma: clinical and animal studies // Nucl. Med. Commun. 1988. V. 9. №12. P. 947-954.
  12. Shiomi S., Kuroki T., Hasegawa I., Nishio H., Azuma K., Ochi H. Accumulation of Tc-99m HMDP in hepatic metastasis from colon carcinoma without detectable calcification // Ann. Nucl. Med. 1996. V. 10. № 3. P. 347-349.
  13. Shih W.J., Han J.K., Magoun S., Wierzbinski B. Bone agent localization in hepatic metastases // J. Nucl. Med. Technol. 1999. V. 27. № 1. P. 38-40.
  14. Ali I., Johns W., Gupta S.M. Visualization of hepatic metastases of medullary thyroid carcinoma on Tc-99m MDP bone scintigraphy // Clin. Nucl. Med. 2006. V. 31. № 10. P. 611-613.
  15. Oh S.J., Won K.S., Moon D.H., Cheon J.H., Ha H.J., Jeong J.M., Lee H.K. Preparation and biological evaluation of 188Re-ethylenediamine-N,N,N',N'-tetrakis(methylene phosphonic acid) as a potential agent for bone pain palliation // Nucl. Med. Commun. 2002. V. 23. № 1. P. 75-81.
  16. Liepe K., Hliscs R., Kropp J., Runge R., Knapp F.F., Jr, Franke W.G. Dosimetry of 188Re-Hydroxyethylidene Diphosphonate in human prostate cancer skeletal metastases // J. Nucl. Med. 2003. V. 44. № 6. P. 953-960.
  17. Ikehira H., Furuichi Y., Kinjo M., Yamamoto Y., Aoki T.Multiple extra-bone accumulations of technetium-99m-HMDP // J. Nucl. Med. Technol. 1999. V. 27. № 1. P. 41-42.
  18. Eising E.G., Jentzen W. Calcification-related absorption in thyroid scintigraphy // Nuklearmedizin. 2010. V. 49. № 1. P. 13-18.
  19. Serafini A.N., Raskin M.M., Zand L.C., Watson D.D. Radionuclide breast scanning in carcinoma of the breast // J. Nucl. Med. 1974. V. 15. №12. P. 1149-1152.